Access Research Institute — research payments reported

By program year

3 rows

Year	Kind	Amount	Payments
2025	Research	$218,210	85
2024	Research	$77,360	18
2023	Research	$10,864	5

Breakdown

Who paid Research payments · program years 2023–2025

Boehringer Ingelheim International GmbH $230,302 86 payments
Chiesi USA, Inc. $61,132 20 payments
GlaxoSmithKline, LLC. $15,000 2 payments

Studies the money was for Research payments · program years 2023–2025

A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis $187,921 73 payments
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) $50,268 15 payments
BI 456906 in NASH F4 - pivotal trial $25,042 2 payments
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis $15,289 10 payments
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multic $15,000 2 payments
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (Triton) $10,864 5 payments
BI 456906 in NASH F2/F3 - pivotal trial $2,050 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.